Zhejiang Medicine Co., Ltd. (SHA:600216)

Market Cap	13.60B -8.5%
Revenue (ttm)	8.96B -0.8%
Net Income	1.24B +27.2%
EPS	1.30 +26.0%
Shares Out	947.91M
PE Ratio	11.06
Forward PE	13.29
Dividend	0.37 (2.48%)
Ex-Dividend Date	Jul 21, 2025

Volume	18,618,511
Average Volume	16,769,369
Open	15.00
Previous Close	14.35
Day's Range	14.41 - 15.00
52-Week Range	11.60 - 16.88
Beta	0.62
RSI	51.90
Earnings Date	Apr 24, 2026

About Zhejiang Medicine

Zhejiang Medicine Co., Ltd. manufactures and sells life nutrition and medical products in China and internationally. The company products include synthetic vitamin E, natural vitamin E, β-carotene, cantharidin, vancomycin hydrochloride, and teicoplanin. It also offers fat-soluble vitamins, retinoids, quinolone antibiotics, anti-resistance antibiotics, and other products, as well as animal nutrition products. In addition, the company provides injectable levofloxacin lactate, injectable vancomycin hydrochloride injections, and injectable teicopla...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 5,815
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600216

Financial Performance

In 2024, Zhejiang Medicine's revenue was 9.38 billion, an increase of 20.29% compared to the previous year's 7.79 billion. Earnings were 1.16 billion, an increase of 170.11%.